GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) announcedan exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX®), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine.
Original Source of GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
